Filing Flows › Arbutus Biopharma (ABUS) › Q2 2026 › vs Q2 2025
Arbutus Biopharma (ABUS) Q2 2026 vs Q2 2025 (year over year)
Arbutus Biopharma's revenue fell $9.7M (-91%) from $10.7M in Q2 2025 to $1.0M in Q2 2026. The biggest changes: Collaborations and licenses −$10.0M (-98%); Revenue from collaborations and licenses +$632K (—); Non-cash royalty revenue −$346K (-66%).
Arbutus Biopharma, Q2 2026: revenue $1.0M (-91% year over year), operating margin -588.2%, net loss $5.1M, operating cash flow −$6.0M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue from collaborations and licenses | $632K | $0 | $632K | — |
| Collaborations and licenses | $202K | $10.2M | −$10.0M | -98% |
| Non-cash royalty revenue | $180K | $526K | −$346K | -66% |
| Revenue | $1.0M | $10.7M | −$9.7M | -91% |
| Other income, net | $821K | $1.0M | −$214K | -21% |
| Net loss | $5.1M | −$2.5M | $7.7M | — |
| Costs & expenses | $7.0M | $11.8M | −$4.8M | -41% |
| Operating costs | $7.0M | $9.3M | −$2.3M | -25% |
| Research & development | $2.9M | $5.5M | −$2.6M | -47% |
| General & admin | $3.9M | $3.3M | $539K | +16% |
| Other operating costs | $213K | $425K | −$212K | -50% |
| Operating cash sources | $7.7M | $16.6M | −$9.0M | -54% |
| Depreciation & amortization | $11K | $11K | $0 | 0% |
| Share-based compensation | $1.6M | $864K | $761K | +88% |
| Cash used in operations | $6.0M | $15.7M | −$9.7M | -62% |
| Net loss absorbed | $5.1M | −$2.5M | $7.7M | — |
| Working capital & other | $2.5M | $19.1M | −$16.6M | -87% |
Questions
How much did Arbutus Biopharma's revenue grow year over year in Q2 2026?
Arbutus Biopharma's revenue fell $9.7M (-91%) from $10.7M in Q2 2025 to $1.0M in Q2 2026.
What drove Arbutus Biopharma's revenue change in Q2 2026?
Collaborations and licenses −$10.0M (-98%); Revenue from collaborations and licenses +$632K (—); Non-cash royalty revenue −$346K (-66%).